MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. | About two and a half years after originating the role ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Gilead Sciences' cell therapy Kite Pharma has ... coming after China's BeiGene paid $45 million upfront to harvest the San Diego-based biotech's iPSC platform to develop NK cell therapies for ...

Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on KYMR stock, giving a Buy rating yesterday.Stay Ahead of the ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...